0001534969-26-000025
SEC filingA pre-commercialization period marked by a 63% revenue decline and sustained operating losses, as management shifts capital allocation toward commercialization activities while targeting cost efficiencies to extend the cash runway.
Sera Prognostics reported Q1 FY2026 financial results that reflect the challenges inherent to an early commercial-stage company preparing for market expansion. Revenue declined 63% year-over-year to $14,000, compared to $38,000 in the prior year period, underscoring the limited payer coverage currently in place for the company's PreTRM test.
Operating loss widened slightly to $9.4 million from $9.2 million in Q1 FY2025. Management indicated that research and development expenses are expected to decrease in 2026 compared to 2025 as the company begins shifting capital allocation toward commercialization activities. This strategic pivot is further supported by management's expectation that general and administrative expenses will also decrease as they seek cost efficiencies to preserve capital for PreTRM commercial opportunities and other strategic initiatives.
The net loss of $8.4 million represents a modest increase from the $8.2 million net loss recorded in the same period last year. Management has been explicit in its outlook, stating that they anticipate continuing to incur net losses for the foreseeable future as they invest in building the commercial infrastructure necessary for broader market adoption.
From a cash flow perspective, net cash used in operating activities was $8.8 million, compared to $7.6 million in the prior year period. The increase in cash usage was primarily attributable to the net loss and changes in operating assets and liabilities. Capital expenditures remained minimal at $8,000, resulting in free cash flow of negative $8.8 million for the quarter.
Despite the ongoing cash consumption, management provided forward-looking commentary on the company's liquidity position. With the new cost structure being implemented, management expects that existing cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements through 2029. This extended runway provides the company with time to execute on its commercialization strategy without immediate financing pressure, particularly notable given that the company currently has no credit facility or committed sources of capital.
The company's investment policy remains focused on preservation of capital and supporting liquidity requirements, a prudent approach given the pre-revenue nature of the business. Management expressed confidence that data expected to be published in coming months and years, together with the current body of evidence, will continue to demonstrate the clinical and economic utility of the PreTRM test, which remains central to the company's commercialization thesis.